ProKidney Inc. - רווח למניה ב-12 החודשים האחרונים PROK

ProKidney Corp. (PROK) is implementing the advanced REACT cell therapy for kidney regeneration, as confirmed by the YoY ttm earnings per share growth chart. The current -10.60 figure determines the magnitude of the yield metric. However, the absence of sales and reliance on external capital create risks, while operational dependence on third-party laboratories necessitates process optimization to stabilize production chains.

Investors must differentiate the actual operational efficiency of ProKidney Corp. (PROK) from temporary accounting anomalies, given the company's critical dependence on external CRO and CMO contractors. By analyzing the trailing twelve months (TTM) earnings per share growth rate, one can strip out one-time subsidies and assess the true profitability dynamics of the business by comparing rolling twelve-month periods to identify a sustainable trend or the risk of overpayment.